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Abstract 
 In this study, a comparison of different methods to predict drug−polymer 
solubility was carried out on binary systems consisting of five model drugs 
(paracetamol, chloramphenicol, celecoxib, indomethacin, and felodipine) and 
polyvinylpyrrolidone/vinyl acetate copolymers (PVP/VA) of different monomer weight 
ratios. The drug−polymer solubility at 25 °C was predicted using the Flory−Huggins 
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model, from data obtained at elevated temperature using thermal analysis methods 
based on the recrystallization of a supersaturated amorphous solid dispersion and two 
variations of the melting point depression method. These predictions were compared 
with the solubility in the low molecular weight liquid analogues of the PVP/VA 
copolymer (N-vinylpyrrolidone and vinyl acetate). The predicted solubilities at 25 °C 
varied considerably depending on the method used. However, the three thermal 
analysis methods ranked the predicted solubilities in the same order, except for the 
felodipine−PVP system. Furthermore, the magnitude of the predicted solubilities from 
the recrystallization method and melting point depression method correlated well with 
the estimates based on the solubility in the liquid analogues, which suggests that this 
method can be used as an initial screening tool if a liquid analogue is available. The 
learnings of this important comparative study provided general guidance for the 
selection of the most suitable method(s) for the screening of drug−polymer solubility. 
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Introduction 
 The development of amorphous drug formulations has attracted a lot of 
attention, both in the pharmaceutical industry and in academic research, owing to the 
potential enhancement of solubility and dissolution rate of poorly water-soluble drug 
candidates.1−3 However, the number of formulations containing drug in the amorphous 
form that have made it through to the market is limited due to the generally poor 
physical stability of the amorphous form.4−6 The high internal free energy of amorphous 
compounds often results in fast recrystallization with the subsequent loss of the 
dissolution rate and solubility advantages.7 Therefore, a key requirement for any 
amorphous formulation to succeed is that it be stable against crystallization during the 
shelf life of the formulation.  
 Incorporation of the amorphous drug into a polymer with a higher glass 
transition temperature (Tg) will generally increase the Tg of the resulting mixture, 
reducing the molecular mobility and thus nucleation and crystal growth of the drug and 
therefore improving the kinetic stability.8 This is commonly known as an amorphous 
solid dispersion and can be defined as a molecular dispersion of the drug in an 
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amorphous polymer matrix. Even though this is a promising approach, it does not 
ensure physical stability during storage, as the drug can still crystallize at temperatures 
well below the Tg.9 Consequently, in order to stabilize the system thermodynamically 
it is essential that the drug be molecularly dispersed in the polymer below its saturation 
solubility, and therefore, determination of drug−polymer solubility is of great 
importance for the rational development of amorphous systems.2,10 However, as 
the  majority of pharmaceutically relevant drugs and polymers are solid (or highly 
viscous) at ambient temperature, measuring the drug− polymer solubility constitutes a 
major challenge.11  Therefore, several differential scanning calorimetry (DSC) 
protocols have been proposed based on determination of equilibrium thermodynamics 
at elevated temperature and extrapolation to room temperature.11−15   
 The initial protocols exploited the melting point depression of a drug in the 
presence of a polymer.12,16,17 The concept of melting point depression to describe the 
interaction between a crystalline polymer and an amorphous polymer can be derived 
from the Flory− Huggins expression of chemical potential of mixing and the condition 
of phase equilibrium.18,19 In theory, melting of a crystal occurs at the temperature when 
the chemical potential of the crystal is equal to the chemical potential of the melt. 
Addition of an amorphous polymer to the crystal may (if miscible) reduce the chemical 
potential of the crystalline material, leading to melting point depression.18,19 
Consequently, by extending the equations presented by Flory− Huggins to fi t 
crystalline drug− polymer systems and assuming that amorphous drug behaves as a 
solvent, it is possible to relate the solubility of a drug in a polymer to the melting point 
depression of the drug.12,20  
 In a protocol developed by Marsac et al.12 physical drug−polymer mixtures of 
known composition were prepared by geometric mixing and analysed by DSC. The 
onset of the bulk melting endotherm (Tm) was considered the equilibrium solubility 
temperature of the given composition. The onset of the melting was chosen to 
eliminate the impact of sample preparation on the Tm.21,22 This protocol was further 
developed by Tao et al.,11 who introduced cryomilling of the physical mixtures before 
DSC analysis in order to compensate for the slow dissolution kinetics by reducing 
particle size to allow for diffusive mixing.7 In this case the end point of the dissolution 
endotherm (Tend) was considered the equilibrium solubility temperature of the given 
composition. The end point (off set) value was chosen because this value represents 
the melting point of the final composition, assuming complete mixing has 
	 4	
occurred.11,13,23  This approach is currently the most commonly used in the literature 
to determine drug−polymer solubility.10,11,13,24−27  
 As a result of the high viscosity of polymers, the dissolution kinetics are slow 
and can potentially (depending on heating rate) exceed the time scale of the DSC 
scan.11 This may result in a higher dissolution end point and ultimately lead to an 
underestimation of the drug− polymer solubility.7 Therefore, Mahieu et al.14  proposed 
a protocol that takes advantage of the fact that recrystallization is generally faster than 
dissolution. In this method, a supersaturated amorphous solid dispersion was 
annealed at diff erent temperatures above the recrystallization temperature until the 
equilibrium solubility was reached.14,28,29 The equilibrium solubility concentration was 
then derived directly from the Tg of the annealed material using the Gordon− Taylor 
relationship.30   
 Even though they vary in detail, the different approaches used to determine the 
drug− polymer solubility reported in the literature can be divided into three general 
thermal analysis methods: (i) the recrystallization method,14 (ii) the dissolution end 
point method,10,11 and (iii) the melting point depression method.12 Despite the 
increased interest in determination of drug solubility in polymers, to the best of our 
knowledge, no comparative study across methods has been conducted. The aim of 
this study was therefore to compare the three aforementioned thermal analysis 
methods, through formal statistical analysis, for the prediction of drug− polymer 
solubility using binary systems consisting of five model drugs (paracetamol, 
chloramphenicol, celecoxib, indomethacin, and felodipine) and 
polyvinylpyrrolidone/vinyl acetate copolymers (PVP/VA) of different 
vinylpyrrolidone/vinyl acetate weight ratios (30/70, 50/50, 60/40, 70/30, and 100/0). 
The model drugs were selected in order to cover a range of general physicochemical 
properties of low molecular weight drugs; i.e., Tm (140− 175 °C), Tg (20−60 °C), and 
molecular weight (Mw, 150−400 g/mol).  
 In addition to the three thermal analysis methods described above, it is possible 
to estimate the solubility of a drug in a polymer from the solubility of the drug in a liquid 
low molecular weight analogue of the polymer using the Flory−Huggins lattice 
model.13,25  Therefore, drug− polymer solubilities obtained using the three thermal 
analysis methods were compared with a prediction based on the solubility of the drugs 
in the liquid monomeric precursors to the copolymer (N vinylpyrrolidone and 
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vinylacetate). The ultimate aim of this comparative study was to provide a general 
guidance for the screening of polymers suitable for glass solutions.  
 
Experimental Section 
Materials. Paracetamol (PCM, Mw = 151.17 g/mol) and chloramphenicol (CAP, Mw = 
323.13 g/mol) were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). 
Celecoxib (CCX, Mw = 381.37 g/mol) was purchased from AK Scientific, Inc. (Union 
City, CA, USA). Indomethacin (IMC, Mw = 357.79 g/mol) was purchased from Hawkins 
Pharmaceutical Group (Minneapolis, MN, USA). Felodipine (FDP, Mw = 384.26 g/mol) 
was purchased from Combi-Blocks, Inc. (San Diego, CA, USA). N-Vinylpyrrolidone 
(NVP, Mw = 111.14 g/mol) and vinyl acetate (VA, Mw = 86.09 g/mol) were purchased 
from Sigma-Aldrich Co. (St. Louis, MO, USA). Plasone K-17 (PVP K17, Mw = 10000 
g/mol), PVP/VA copolymer E-335 (PVP/ VA 335, Mw = 28000 g/mol), PVP/VA 
copolymer E-535 (PVP/VA 535, Mw = 36700 g/mol), PVP/VA copolymer E-635 
(PVP/VA 635, Mw = 38200 g/mol), and PVP/VA copolymer E-735 (PVP/VA 735, Mw 
= 56700 g/mol) were kindly supplied by Ashland Chemical Co. (Columbus, OH, USA). 
Since the PVP/VA copolymers were sourced as solutions, they were converted to the 
solid forms by spray drying. The supplied liquids were diluted with ethanol to form 5% 
(w/w) solutions and processed, using the Mini Spray Dryer B-290 from Büchi (Flawil, 
Switzerland) in the open pressure mode with air as drying gas, applying the following 
conditions: inlet temperature 140 °C, aspirator rate 100%, and pump speed 30%. 
These parameters resulted in an outlet temperature of around 80 °C.   
Liquid Analogue Solubility Approach. Solubility Measurements. The solubility of the 
different drugs in the liquid analogues NVP and VA was determined using the shake-
flask method. An excess of crystalline drug was added to a capped glass tube 
containing 1 mL of the liquid analogue and shaken for 72 h using a mechanical rotor 
from Heto Lab Equipment (Birkerod, Denmark). Samples were withdrawn, filtered 
using a 0.2 μm PTFE hydrophobic syringe filter from Merck Millipore Ltd. (Darmstadt, 
Germany), and diluted with mobile phase to appropriate concentrations. The diluted 
samples were assayed using a HPLC system composed of an L-7100 pump, an L-
7200 auto sampler, a T-6000 column oven, and a D-7000 interface, all from Merck-
Hitachi LaChrom (Tokyo, Japan). A reverse phase X-Bridge C-18 column (4.6 Å~ 150 
mm, 3.5 μm) from Waters (Milford, MA, USA) was used for the separation, and the 
mobile phase consisted of methanol and 0.0025 M potassium dihydrogen phosphate 
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aqueous buffer (72:28 v/v) adjusted to pH 3 with phosphoric acid. A variable 
wavelength ultraviolet L-7450A diode array detector from Merck-Hitachi LaChrom 
(Tokyo, Japan) was used to detect signals at wavelengths 280, 280, 250, 270, and 
230 nm and retention times 1.62, 2.03, 8.06, 4.04, and 11.95 min for PCM, CAP, CCX, 
IMC, and FDP, respectively.  
Recrystallization Method. Sample Preparation.  Supersaturated amorphous solid 
dispersions were prepared by a fi lm casting method. The drug and polymer (80:20 or 
85:15 w/w, 500 mg) were dissolved in 5 mL of acetone: ethanol (80:20 v/v) and cast 
onto a Teflon coated 76 Å~  26 mm Menzel glass. The solvent was evaporated on a 
Jenway 1100 hot plate from Bibby Scientific Ltd. (Staffordshire, U.K.) using a plate 
temperature of 150 °C. The dried samples were scraped of the Teflon coated glass 
plate and gently ground using a mortar and pestle.  
Thermal Analysis.  The cast film powders and pure compounds were analyzed using 
a Q2000 DSC from TA Instruments Inc. (New Castle, DE, USA). Sample powders 
(2−  3 mg) were scanned under 50 mL/min pure nitrogen gas purge using Tzero 
aluminum hermetic pans with a perforated lid. The temperature and enthalpy of the 
DSC instrument were calibrated using indium. The melting temperature (Tm, onset), 
melting enthalpy (ΔHm), glass transition temperature (Tg, inflection), and heat capacity 
change (ΔCp) were determined using the Universal Analysis 2000 (version 4.5A) 
software.   
Solubility Determination. The supersaturated amorphous solid dispersions were 
loaded into the DSC and annealed at different temperatures below the Tm of the 
particular drug under investigation for 3 h to crystallize the excess drug in the mixture 
and to reach equilibrium solubility. After annealing, the sample was cooled to −10 °C 
and ramped at a rate of 5 °C/min to determine the Tg of the annealed material. The 
concentration of drug remaining in the polymer matrix was then derived directly from 
the Tg of the annealed material. In order to determine the composition dependence of 
the Tg, physical mixtures of drug−polymer of known composition were prepared using 
a mortar and pestle. The samples were then heated above the Tm of the pure drug, 
quench cooled to −10 °C in situ in the DSC, and ramped at a rate of 5 °C/min to 
determine the Tg. For a detailed description of the method, please refer to Mahieu et 
al.14 and Knopp et al.28  
Solid State Characterization. X-ray powder diffraction (XRPD) analysis was performed 
using an X’Pert PRO MRD diffractometer from PANalytical (Almelo, The Netherlands) 
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equipped with a TCU 100 temperature control unit and an X’Celerator detector using 
nickel-filtered Cu Kα radiation (λ = 1.5406 Å) at 45 kV and 40 mA. Approximately 1 mg 
of sample powder was placed on zero background Si plates and measured over the 
angular range 3−40° 2θ at a scan rate of 1.20° 2θ/min. The diffractograms were 
analyzed using the X’Pert Data Viewer (version 1.2) software.  
Dissolution End Point Method.  Sample Preparation. Drug and polymer mixtures 
with different compositions were first mixed using a mortar and pestle followed by 
mixing in a MM 200 ball mill mixer from Retsch GmbH (Haan, Germany). The individual 
materials were kept in a drying chamber for at least 24 h at 50 °C before sample 
preparation. In a typical milling procedure, pure drug, or drug−polymer powder 
samples of 500 mg were loaded in 25 mL stainless steel milling containers with two 
stainless steel balls (15 mm in diameter) and milled at 20 Hz. A predefined milling time 
of 2 min was chosen, which was subsequently followed by a 2 min cooling time. The 
number of milling−cooling cycles to be used for each drug−polymer combination was 
determined by measuring the melting end point of the mixture, where no further 
decrease in the melting end point was observed with increased number of 
milling−cooling cycles. Longer milling time enhanced the dissolution rate of the 
crystalline drug into the polymer but decreased the sensitivity of the DSC 
measurement due to increased amorphous content (observed by XRPD). Thus, fewer 
milling−cooling cycles were used for mixtures containing lower drug loadings.   
Thermal Analysis. Samples were analyzed using the power compensation DSC8000 
from PerkinElmer (Waltham, MA, USA). Nitrogen was used as the purge gas for low 
speed scanning. Approximately 8−10 mg of freshly ball-milled sample was packed into 
an aluminum pan with a perforated lid. Melting point end point determination was 
conducted at a heating rate of 1 °C/min from 20 to 200 °C. The end point of the melting 
endotherm (Tend) was calculated from the intercept point of the endothermic trace 
and the postmelting baseline.   
Solid State Characterization. The solid state properties of the ball-milled samples were 
determined using a MiniFlex II Xray powder diffractometer from Rigaku Corp. (Tokyo, 
Japan). Radiation was generated from a copper source operating at a voltage of 30 
kV and a current of 15 mA. The test samples were packed into a glass sample holder 
and scanned from 0 to 40° 2θ, using a step width of 0.01° 2θ and a scan rate of 1° 
2θ/min; continuous mode was used. There were certain levels of increased 
amorphous halo background in the XRPD pattern of ball-milled samples in comparison 
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to crystalline drug and amorphous polymer physical mixtures, but the polymorphic 
form of all crystalline drugs was determined to be the same as that of the starting drug 
materials.  
Melting Point Depression Method.  Sample Preparation. Physical mixtures (w/w) of 
drug and polymer were prepared by ball milling at 400 rpm for 10 min with a PM 100 
planetary ball mill from Retsch GmbH (Haan, Germany) at room temperature. A total 
amount of 500 mg was loaded to the stainless steel milling container with a volume of 
25 mL, and two stainless steel balls (15 mm in diameter) were used. Care was taken 
to ensure that no polymorphic transition occurred and crystalline API was still present 
at the end of milling (confirmed by XRPD).26 Collected samples were stored in a 
desiccator over silica gel at 5 °C until use.   
Thermal Analysis. The melting events of the physical mixtures were measured using 
a Diamond DSC from PerkinElmer (Waltham, MA, USA) with HyperDSC and a ULSP-
130 cooling system from ULSP BV (Ede, The Netherlands) operated under a nitrogen 
flow of 40 mL/min. The gas flow was controlled using a Thermal Analysis Gas Station 
(TAGS) from PerkinElmer (Waltham, MA, USA). The instrument was calibrated for 
both melting onset and enthalpy with indium. Before the measurement, samples (5−8 
mg) in standard aluminum DSC pans were first annealed for 2 h in an oven from 
Memmert GmbH (Schwabach, Germany) at a temperature 10 °C above the glass 
transition temperature of the polymer. The 2 h annealing time was chosen based on a 
comparison of the heat of fusion values obtained for the 90:10 w/w drug−polymer 
physical mixtures of nonannealed sample and samples annealed for 2, 4, and 6 h. 
Samples were then cooled down to room temperature, and the final sample weight 
was determined. The DSC program used was as follows: samples were fi rst heated 
to 100− 120 °C at a heating rate of 10 °C/min, and then a heating rate of 1 °C/min was 
applied to obtain the melting temperature value as close to the equilibrium as possible. 
All curves were evaluated, and the values of melting point (Tm, onset) and melting 
enthalpies (ΔHm) were determined. In order to determine the Tg of the drug− polymer 
mixtures, the samples were preheated in the DSC pans from 100 ° C to a temperature 
above the Tm  of drug at a 10 °C/min heating rate and then cooled to 30− 40 ° C below 
the expected Tg  at a cooling rate of 300 °C/min, and then a step scan method was 
applied to determine the Tg. For the step scan, the samples were heated to 30− 40 °C 
above the expected Tg  at 5 ° C/min in 2 °C steps. A 1 min isothermal step was applied 
between each of the dynamic steps.  
	 9	
Solid State Characterization.  XRPD analysis on all physical mixtures was conducted 
using a Rigaku Miniflex II Desktop Xray diffractometer (Tokyo, Japan) with a Haskris 
cooling unit (Grove Village, IL, USA). The tube output voltage used was 30 kV, and 
tube output current was 15 mA. A Cu tube with Ni filter suppressing Kβ  radiation was 
used. Measurements were taken from 5 to 40° 2θ at a scan rate of 0.05°  2θ /s. A zero 
background Si plate was used during measurements to support the sample.  
Density Determination.  The amorphous densities of the materials were determined 
using an AccuPyc 1330 helium pycnometer from Micromeritics Instruments Corp. 
(Norcross, GA, USA). Prior to the measurements, approximately 1 g of the samples 
was melt quenched to remove any sorbed moisture and to obtain the amorphous form. 
The samples were weighed before analysis and purged with 19.5 psig dry helium. The 
reported results are averages of 10 consecutive measurements.   
 
Theoretical Considerations 
Prediction of Drug− Polymer Solubility from Drug−  Analogue Solubility. 
Considering that a low molecular weight liquid analogue constitutes the lattice of a 
polymer, the molecular volume, activity coefficient, and experimental solubility in the 
analogue can be used to estimate the solubility of the drug in the polymer.25 The 
activity coefficient in an analogue (γ analogue) is the ratio of ideal mole fraction 
solubility (Xid) and the experimental mole fraction solubility of drug in the analogue 
(Xdrug). The Xdrug in the analogue is obtained experimentally from HPLC analysis as 
described above, and Xid is calculated using:25 
÷
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where ΔHm and Tm are the enthalpy of fusion and melting temperature for the drug, 
respectively, ΔCp is the heat capacity change at the glass transition of the amorphous 
drug, R  is the gas constant, and T  is the temperature for which the solubility estimate 
is desired. The γ analogue can now be used to calculate the activity coefficient in the 
polymer (γ polymer) at the solubility limit using:13 
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where MVdrug and MVanalogue are the molar volume of drug and analogue, respectively, 
mdrug and mpolymer are the ratio of the volume of drug and polymer to the analogue, 
respectively, and vdrug and vpolymer  are the volume fraction of drug and polymer, 
respectively. Finally, the mole fraction solubility of crystalline drug in the polymer can 
be derived from the ratio of Xid to γpolymer and converted to mass fraction (w/w) for 
comparison with the experimentally determined solubility.  
Prediction of Drug−Polymer Solubility from DSC Data.  The experimental solubility 
of drug in the polymer at elevated temperature was determined using the analytical 
protocols described in the Experimental Section. The data sets were fitted with the 
Flory− Huggins model in order to predict the solubility at ambient temperature by 
extrapolation:18 
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Eq. 3. 
where ΔHm and Tm are the enthalpy of fusion and melting temperature for the pure 
drug respectively, R is the gas constant, λ is the molar volume ratio of the polymer and 
drug, χ is the Flory−Huggins interaction parameter. T is the annealing temperature, 
onset temperature of melting, or dissolution end point temperature, depending on the 
method in question, and vdrug is the volume fraction of drug derived from: 
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Eq. 4.  
where ρdrug and ρpolymer  are the densities of drug and polymer, respectively, and 
Xdrug  is the mass fraction of drug.  
Statistical Analysis.  The aim of the statistical analysis was to provide a prediction of 
the drug−polymer solubility at storage temperature (25 °C). As measurements at such 
low temperatures are infeasible (or even impossible), one has to rely on extrapolations 
of data obtained at elevated temperatures from the Flory− Huggins model.18 The 
predictions of the drug solubility at room temperature were reported as a central 
estimate (the least-squares estimate) and a 95% prediction interval in the present 
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study. The predicted solubility was derived from eqs. 3 and 4 by inserting the 1 − 
α prediction interval for a future observation of χ given by:  
N
st N
11ˆ ˆ1,2/ +××± - cac  
Eq. 5. 
where χ̂ is the least-squares estimate of the interaction parameter, χ̂ s is the standard 
deviation of χ̂ , and tα/2,N−1  is the α /2 quantile in the t -distribution with N −  1 degrees 
of freedom. In order to make a proper statistical analysis it is important to realize which 
variable is subject to experimental noise.  
The Recrystallization Method.  In the recrystallization method, vdrug was subject to error 
as it was derived from the glass transition temperature of the annealed material. 
However, as vdrug cannot be expressed analytically by rearranging the Flory−Huggins 
model, the statistical analysis was characterized as an implicit regression problem. 
The least-squares estimate χ̂ was found by minimizing the residual sum-of-squares 
given by: 
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to the implicit nature of the problem, the implementation of the analysis requires 
numerical software, such as MatLab from MathWorks (Natick, MA, USA), which was 
used in the current work. The standard deviation of χ is given by ( )( ) ( )cc
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where ( )cˆJ is the Jacobian matrix at χ̂ which was directly obtainable from the nonlinear 
least-squares routine in MatLab.  
The Dissolution End Point Method and the Melting Point Depression Method.  For the 
dissolution end point and melting point depression methods, the experimentally 
uncertain variable was the melting point, and therefore, the regression problem can 
be formulated explicitly. The residual sums-ofsquares were, for these two methods, 
given by ( ) ( ) ( )( )å
=
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N
i
fittedtmeasuremen iTiTSSR
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2;cc , where N is the number of 
measurements. However, it was observed that when the dependent variable was the 
melting point, the leverage of the fitted values ( )
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= was highly variable. 
Points with high leverages have a larger influence on the fit, which was undesirable 
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as all data points should contribute equally. In order to correct for this, the residual 
sum-of-squares was studentized: ( ) ( ) ( )( )å
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1 cc . Due to 
the simpler structure of the regression problem for these two experimental methods, 
most software will be able to calculate studentized residuals and the standard 
deviation of χ̂ directly. For consistency, however, MatLab was also used for this 
regression problem.  
Outlier Detection.  Data points that did not follow the pattern described by the Flory− 
Huggins model can be described as outliers. Removal of outliers from the sample can 
improve the power of the predictions radically. Therefore, outlier detection was done 
by calculating Cook’ s distance of the data points.31 Points, with Cook’ s distance larger 
than three times the mean Cook’ s distance, were removed from the particular sample 
analysis. Upon removal, the model was refitted on the new outlier-reduced sample 
and the Cook’ s distance was recalculated. This procedure was iterated until no 
outliers were detected.  
 
Results and Discussion 
 Liquid Analogue Solubility Approach. The drug− polymer solubility can be 
estimated from the drug solubility in a liquid low molecular weight analogue using the 
Flory− Huggins lattice model by assuming that the analogue constitutes the lattice of 
a polymer and that the interactions and combinatorial entropy of mixing in the 
drug−analogue and drug−polymer systems are similar.13,25  
 In this study NVP and VA were used as the analogues because they are the 
monomeric precursors of the PVP/VA copolymer investigated in this study and 
structurally identical with the repeat units after polymerization. The solubility of the 
different drugs in NVP and VA was obtained experimentally from HPLC analysis as 
described above, and the thermodynamic values used to calculate the activity 
coefficient in the analogues and polymers were obtained from DSC analysis. The 
solubility of the five different drugs in the respective PVP/VA copolymers was 
calculated from the solubility in the liquid NVP and VA monomers and the 
thermodynamic values given in Table 1 using eqs. 1 and 2. The results are given in 
Table 2.  The solubility (w/w) ranged from 0.00 for PCM in VA to 0.71 for CAP in NVP, 
and the solubility for all the different drugs was higher in NVP than in VA. After 
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correcting for the reduced entropy of mixing, the predicted solubilities in the pure 
homopolymers (PVP and PVAc) were reduced drastically compared to those in the 
analogues. In order to predict the solubility in the copolymer, the solubility in each of 
the two homopolymers was determined and multiplied by the weight fraction in the 
copolymer.  
 The influence of molecular weight on the predicted solubility is negligible for 
high molecular weight polymers as the term that compensates for molecular weight in 
eq. 2, 1/mpolymer, approaches zero.25 Therefore, the solubility of the drugs in the 
copolymers can be compared without accounting for the difference in molecular weight 
of the copolymers.  
It is important to note that this approach provides an estimate of the solubility in the 
liquid state rather than in the solid glass and, therefore, should be evaluated with 
caution.13  Nevertheless, this approach might still provide valuable indications on the 
solubility of a drug in a polymer if a liquid analogue of the polymer is available.29  A 
review of the Sigma- Aldrich (St. Louis, MO, USA) product range revealed that, in 
addition to PVP and PVAc, liquid analogues of pharmaceutically relevant polymers are 
available for polymethacrylates (Eudragit), poly(vinyl alcohol) (PVA), poly(acrylic acid) 
(Carbomer), polyethylene glycol (PEG), and poly(ethylene oxide) (PEO), but not for 
cellulose ethers (e.g., hydroxypropylmethylcellulose, HPMC) and polysaccharides 
(e.g., chitosan).  
Recrystallization Method.  Thermodynamically, the equilibrium solubility can be 
measured in at least four different ways, of which the shake-flask method (applied in 
the liquid analogue solubility approach) is probably the most commonly used. Here the 
increase of solution concentration is measured from an undersaturated solution at 
constant temperature.7 However, this method is impracticable for solid drug− polymer 
systems due to the solid nature or high viscosity of polymers. The recrystallization 
method approaches the equilibrium in a different but thermodynamically equal way, by 
measuring the decrease of solution concentration from a supersaturated solution at 
constant temperature. As this method relies on the recrystallization of the 
supersaturated drug from the polymer matrix, it is only feasible to determine the 
equilibrium solubility above the recrystallization temperature of the supersaturated 
system.14 This is because reaching the equilibrium becomes increasingly more time-
consuming at temperatures close to the recrystallization temperature due to 
decreased molecular mobility, which inhibits nucleation and crystallization.28   
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 Parameters including drug solubility, polymer Tg and viscosity, degree of 
supersaturation, and annealing temperature as well as time affect the nucleation and 
crystallization rate of drugs in supersaturated amorphous solid dispersions. Therefore, 
it is important to evaluate the drug− polymer ratio and annealing time/temperatures 
every time a new drug− polymer system is investigated.28 Finding the right drug− 
polymer ratio is a balance between having a too unstable system that recrystallizes 
before the annealing temperature is reached and a too stable system that will not 
recrystallize during annealing. The annealing time can be established by monitoring 
the exothermic recrystallization event during the annealing step, and the process is 
considered to be in equilibrium after the signal reaches a baseline. However, as the 
crystallization rate decreases rapidly when the concentration approaches equilibrium 
solubility,9 the true equilibrium may not be reached. Nevertheless, in this study, a 3 h 
annealing time and 80:20 w/w ratios of drug− polymer were found to be suitable for 
the PCM, CAP, CCX, and FDP systems and 85:15 w/w for the IMC system.   
 In the original method proposed by Mahieu et al.,14 the equilibrium solubility 
concentration after annealing is derived from the Tg of the annealed material using the 
Gordon− Taylor relationship. However, in this study the composition dependence of 
the Tg did not correlate with the Gordon−Taylor relationship (data not shown), and 
therefore, this could not be used to determine the equilibrium solubility after annealing. 
As an alternative, the experimental composition dependence of the Tg in all systems 
was used to derive the equilibrium solubility concentration after annealing. Using the 
annealing temperature and drug fraction, the interaction parameter χ was determined 
from eqs. 3  and 4 . The Tg of the annealed materials and the corresponding 
equilibrium solubilities of the various drugs in the polymers are listed in Table 3. After 
annealing, it was confirmed that only one Tg was detectable in DSC thermograms for 
all systems. It was possible to obtain data at annealing temperatures from 115 to 150 
°C. At temperatures below 115 °C the time to reach equilibration exceeded the 3 h of 
annealing, and above 150 °C the drug concentration was not sufficient to saturate the 
mixture. As anticipated from the liquid analogue solubility approach, the CAP, CCX, 
and IMC systems exhibited the lowest degree of recrystallization and the PCM and 
FDP systems the highest.  
Dissolution End Point and Melting Point Depression Methods.  As described in 
the Introduction, it is possible to relate the magnitude of melting point depression 
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(chemical potential reduction) to the solubility of a drug− polymer system using the 
Flory− Huggins model.18,19  
 Pure crystalline materials melt at a temperature when the chemical potential of 
the crystalline and liquid states is equal. If an “impurity” , such as a polymer, is added 
to the crystalline material, the chemical potential can be reduced compared to that of 
the pure crystalline material.18  This reduction in chemical potential can be observed 
using DSC through detection of a depressed melting point.11,12  For drug− polymer 
systems this phenomenon is observed when the dissolution of the crystalline drug into 
the amorphous polymer is favoured by the thermodynamics of mixing due to solid state 
interactions between the drug and polymer.12  Consequently, it is expected that the 
depression of the melting point is greater if mixing is exothermic compared to a thermal 
or endothermic mixing and not present for immiscible systems.13   
 The level of mixing of the components as well as the particle size will affect the 
accuracy of the DSC measurements as the dissolution requires transport of molecules 
into the polymer matrix. If the components are poorly mixed and contain large 
particles, mixing requires transport over long distances, which will result in a thermal 
lag. This can be accounted for by decreasing the heating rate or introducing milling of 
the sample to reduce the particle size and increase the level of mixing. Intensive low-
temperature milling of physical mixtures can increase the drug− polymer surface 
interactions and reduce diffusive mixing to a point where dissolution of the crystalline 
drug is completed during the thermal analysis; however, milling is also known to 
potentially render the drug (partially) amorphous.32 Consequently, for the dissolution 
end point method, a degree of amorphization is promoted, but complete amorphization 
should be avoided. In contrast, for the melting point depression method, as the drug− 
polymer solubility is derived from the chemical potential difference in the 
Flory−  Huggins model, it is important that the drug fraction be 100% crystalline.  
 The determination of the melting point of the crystalline drug represents the 
ideal case assuming that it can be obtained in an equilibrium transition state.21 
Therefore, the melting point is ideally recorded at zero heating rate;11 however, as this 
is not possible in practice, the heating rate should be slow enough to induce molecular 
mixing. Conversely, from a practical point of view, it is also desirable to reduce the 
duration of the DSC run, and thus, the optimal heating rate depends on the molecular 
mobility of the system and, hence, the viscosity and Tg of the polymer. If the Tg of the 
polymer is above the temperature of equilibrium, the molecular mobility in the polymer 
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might be so low that mixing of the components becomes slower than the time scale of 
the DSC measurement.11 Therefore, the application of these methods to predict 
drug−  polymer solubility is limited to polymers with a relatively low Tg. In this study, 
data was only recorded at temperatures above the Tg of the polymer, and a heating 
rate of 1 ° C/min was applied as this rate was believed to be sufficiently low to induce 
molecular mixing while providing data relatively fast.  
 Finally, it is still debated whether to use the onset or endpoint values of melting 
to determine the Flory− Huggins interaction parameter. While both methods are still 
being applied, the end point is currently most commonly used to determine the 
solubility of drugs in polymers in the literature.10,11,13,24,25,27 The underlying argument 
is that this value represents the melting point of the final composition, assuming that 
complete mixing has occurred.11,13,23 Nevertheless, more research is needed in order 
to ultimately determine what the most appropriate method is. Therefore, in this study 
both the onset and end point values were obtained from the two different methods and 
compared. The data obtained from the two different methods can be found in Table 3, 
and the interaction parameter χ from the dissolution end point and melting point 
depression was derived directly from the data by applying eqs. 3 and 4. From Table 
3 it can be seen that both methods demonstrated some degree of melting point 
depression, suggesting that all systems were miscible. As expected, the onset values 
were lower than the end point values using the two different methods. However, for 
the FDP:PVP K17 system the onset values were higher than the end point values, 
indicating a discrepancy. As both methods use the same heating rate, this discrepancy 
could be due to the intimate milling (and perhaps partial amorphization) applied in the 
dissolution end point method.  
Comparison of the Different Methods.  The predicted solubility at 25 ° C of the five 
drug− copolymer systems using the four different methods can be found in Figure 
1 and Table 4  along with χ  values and 95% prediction intervals. Note that the 
estimates from the liquid analogue solubility approach do not include a 95% prediction 
interval. This is because the estimates were based on a single-point determination 
obtained at 25 ° C and thus not obtained from extrapolation. Representative 
equilibrium solubility curves of the IMC:PVP/ VA 735 system using the data obtained 
from the three different thermal analysis methods are shown in Figure 2. As the value 
of χ is influenced by all factors in the Flory− Huggins model, it is not comparable 
between the different systems or methods. Therefore, the evolution of the solubility 
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curve or the predicted solubility at 25 °C rather than χ  should be used for comparison. 
The predicted solubilities at 25 °C vary considerably depending on whether 
(dissolution) end point or (melting point depression) onset values are used. Defining 
which of the methods is better requires more eff ort to understand the difference in 
detail and is beyond the scope of the current work; however, this is certainly something 
which should be considered when selecting experimental method. 
 From Figure 1 and Table 4 it is evident that the recrystallization and melting 
point depression methods rank the predicted solubility in the same order, IMC-PVP/VA 
735 > CCX-PVP/VA 635 > CAP-PVP/VA 535 > FDP-PVP K17 > PCM− PVP/VA 335. 
Except for the FDP-PVP K17 system, this ranking is identical to the predicted solubility 
obtained from the dissolution end point method, but different from that predicted by 
the liquid analogue solubility approach. However, the magnitude of the predicted 
solubilities from the recrystallization method and melting point depression method 
correlated well with the predictions from the liquid analogue solubility approach. This 
suggests that this method can be used to screen for drug solubility in polymers if a 
liquid analogue is available.  
 The solubility predictions at 25 °C based on the recrystallization method were 
consistently higher than the predictions based on dissolution end point method (except 
for FDP-PVP K17). This difference was to some extent expected, as the 
thermodynamics behind the two methods are fundamentally different. The 
recrystallization method approaches equilibrium solubility from the supersaturated 
state, and the equilibrium thermodynamics are driven by recrystallization kinetics. In 
contrast, the dissolution end point method approaches equilibrium solubility from an 
undersaturated state and the equilibrium thermodynamics are thus driven by 
dissolution kinetics.  
 In addition to being dependent on temperature and viscosity,25 the 
recrystallization and dissolution kinetics slow down when the concentration 
approaches equilibrium solubility. In fact, the recrystallization kinetics may be so slow 
that it is not detectable in the DSC and, therefore, the system can falsely be considered 
in equilibrium.28 This could give a reason to believe that the recrystallization method 
might be overestimating the solubility. Furthermore, as the dissolution end point 
method relies on dissolution kinetics that are expected to be slower than 
recrystallization kinetics,14 an underestimation of the solubility is expected. It is 
therefore rational to assume that the true solubility is somewhere between that 
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predicted by the recrystallization and dissolution end point methods. Even though this 
is a hypothesis left unverified in this study, it could explain why the predicted solubility 
was consistently higher when using the recrystallization method compared to the 
dissolution end point method.  
 A way of limiting the prediction error is to increase the annealing time and lower 
the heating rate to allow for equilibrium to be reached for the recrystallization method 
and dissolution end point method, respectively. However, due to the previously 
mentioned slow kinetics, this would drastically increase the duration of the 
experiments and probably not impact the solubility prediction significantly.  
 In the case of the melting point depression method, the evaluation of the 
prediction is more complex. As the method is not based on equilibrium 
thermodynamics, it is difficult to say whether the method is under- or overestimating 
the solubility. However, this could be investigated by annealing the sample at the 
determined Tm until equilibrium has been reached and subsequent scanning for a 
residual dissolution endotherm, as proposed by Sun et al.7 The presence of a 
dissolution endotherm after annealing indicates that the dissolution is not completed 
and that the “true” Tm is located above the annealing temperature. This approach is 
very time-consuming and is therefore laborious compared to the methods used in this 
study. Due to the nature of the method and as the solubility data from the melting point 
depression method was not significantly different from that of the recrystallization 
method, it is expected that the melting point depression method is also likely to 
overestimate solubility. The advantages and disadvantages of the four different 
methods are summarized in Table 5.  
 The negative χ value, signifying miscibility predicted for all systems in this study, 
is, to some extent, also supported by the experimental deviation from the theoretical 
Gordon−Taylor relationship as mentioned previously (data not shown). The 
Gordon−Taylor relationship is based on ideal mixing behaviour (additivity) of the two 
components. Deviations from the ideal behavior are the result of entropy effects 
beyond combinatorial mixing such as strong intermolecular interactions.33 As cohesive 
intermolecular interactions (e.g., hydrogen bonds) favour miscibility,12 it is rational to 
assume that strong/numerous interactions indicate good miscibility between the 
components.  
 As can be derived from the data presented in Table 4, the predictions based on 
the recrystallization method were more precise (relatively) than the predictions based 
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on the melting point depression and dissolution end point methods. This is probably a 
result of the nature of these methods as the interaction parameter is more sensitive to 
experimental uncertainty, at temperatures closer to the melting point of the pure drug. 
Even a small change in the melting temperature will have a large impact on χ and thus 
also the curve fitting and predicted solubility at 25 ° C. Therefore, it is recommended 
that data points are only obtained for compositions lower than 90% drug. Conversely, 
at lower drug contents the dissolution kinetics can potentially exceed the time scale of 
the experiment depending on heating rate. In order to account for thermal lag and the 
influence of the heating rate on the phase equilibrium temperature, Tao et al.11 
proposed an extrapolation of the temperature to zero heating rate. However, the 
validity and linearity of these extrapolations has still not been confirmed. Generally for 
a glass solution to be pharmaceutically relevant, the drug− polymer solubility should 
ideally be higher than 20% w/w at typical storage temperatures.34 Consequently, 
based on the findings of this study, a decision tree for the screening of polymers 
suitable for glass solutions has been proposed in Figure 3. It is important to emphasize 
that the decision tree is designed for the selection of polymers suitable for glass 
solutions only and thus do not regard considerations of kinetic stability. This means 
that polymers classified as unsuitable for glass solutions according to the decision tree 
are not necessarily also unsuitable for (kinetically stabilized) solid dispersions.   
 The proximity of the Hildebrand solubility parameter of the drug to that of the 
copolymer (± 7.5 MPa1/2) has been proposed to indicate miscibility between the 
compounds.35 This could potentially give valuable indications on the drug−  polymer 
solubility and speed up the screening process (by excluding unpromising polymers 
early in the screening). However, no direct correlation between the proximity of the 
Hildebrand solubility parameter and drug− polymer or drug−  analogue solubility was 
found in this study (data not shown). Therefore, it is recommended that the screening 
be initiated by determining the solubility in liquid analogues of pharmaceutically 
relevant polymers if available. If the drug is not freely soluble (<10% w/w) in an 
analogue of the polymer, it is most likely also not soluble in the polymer, and therefore, 
a change to a structurally different polymer should be considered. Having established 
the most promising polymer candidates from the liquid analogue solubility approach, 
the solubility of the drug in the polymers can now be predicted from one or more of the 
three thermal analysis methods. Which of these three different thermal analysis 
methods are optimal for the prediction of drug− polymer solubility is dependent on the 
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thermal properties of both the drug and polymer. If the Tg of the polymer is higher than 
the Tm of the drug or the difference between the Tm of the drug and Tg of the polymer 
is less than 20 °C, the mixing of the components might be slower than the time scale 
of the DSC measurement and, therefore, the recrystallization method should be used. 
On the other hand, if the difference between Tg of the polymer and the Tg of the drug 
is less than 20 °C, the experimental composition dependence of the Tg  might not be 
sufficient to derive the equilibrium solubility concentration with satisfactory precision 
after annealing. In this case, it is recommended that drug− polymer solubility be 
predicted from the dissolution end point or melting point depression method. If none 
of the above restrictions apply, all three thermal analysis methods can be used to 
predict the drug− polymer solubility. As mentioned previously an overestimation of the 
solubility should be expected when using the recrystallization and melting point 
depression methods and an underestimation should be expected when using the 
dissolution end point method. The data obtained at elevated temperature from the 
thermal analysis method(s) is then fitted with the Flory− Huggins model and 
extrapolated in order to predict the solubility at ambient temperature. If the drug is not 
freely soluble (>10% w/w) in the polymer, then a change to another polymer or 
formulation strategy should be considered. Finally, for the most promising polymer(s), 
the drug− polymer solubility can be confirmed with long-term stability at dry conditions 
at room temperature.  
 
Conclusions 
 In this work, a comparative study of different methods to predict drug−polymer 
solubility was carried out. The drug− polymer solubility at 25 °C was predicted by 
extrapolation of data obtained at elevated temperature using the Flory−Huggins 
model. The predictions from the recrystallization and melting point depression 
methods provided similar predictions that were consistently higher than the predictions 
made from the dissolution end point method. Furthermore, the recrystallization method 
provided smaller confidence intervals of the predictions (relatively) compared to the 
dissolution end point and melting point depression methods due to a better fit of the 
obtained data to the Flory−Huggins model. All methods could successfully produce 
data with satisfactory reproducibility that fitted relatively well with the Flory−Huggins 
model, and thus, no limitations to the methods were discovered. The learnings of this 
comparative study provided a general guidance for the selection of the most suitable 
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thermal analysis method for the screening of drug−polymer solubility. However, 
defining which of the thermal analysis methods is superior requires more effort to 
understand in detail and will have to be investigated in future work.  
 
Acknowledgements 
 The authors would like to thank E. B. Jørgensen of the Department of Biologics 
and Pharmaceutical Science at H. Lundbeck A/S for his contribution to the HPLC 
measurements. This publication has emanated from research supported in part by the 
Irish Research Council and Eli Lilly S.A. through an Irish Research Council Enterprise 
Partnership Scholarship for C.M.B., in part by The Royal Society in the form of 
Industrial Fellowship awarded to G.A., and in part by a research grant from Science 
Foundation Ireland (SFI) under Grant Number SFI/12/RC/2275 (for A.M.H., L.T., K.P., 
and A.K.).  
 
References 
1. Hancock, B. C.; Zografi, G. Characteristics and significance of the amorphous state 
in pharmaceutical systems. J. Pharm. Sci. 1997, 86 (1), 1−12. 
2. Leuner, C.; Dressman, J. Improving drug solubility for oral delivery using solid 
dispersions. Eur. J. Pharm. Biopharm. 2000, 50 (1), 47−60. 
3. Yu, L. Amorphous pharmaceutical solids: preparation, characterization and 
stabilization. Adv. Drug Delivery Rev. 2001, 48 (1), 27−42. 
4. Serajuddin, A. T. Solid dispersion of poorly water-soluble drugs: early promises, 
subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999, 88 (10), 
1058−1066.  
5. Craig, D. Q. The mechanisms of drug release from solid dispersions in water-soluble 
polymers. Int. J. Pharm. 2002, 231 (2), 131−144. 
6. Grohganz, H.; Priemel, P. A.; Lobmann, K.; Nielsen, L. H.; Laitinen, R.; Mullertz, A.; 
Van den Mooter, G.; Rades, T. Refining stability and dissolution rate of amorphous 
drug formulations. Expert Opin. Drug Delivery 2014, 11 (6), 977−989. 
7. Sun, Y.; Tao, J.; Zhang, G. G.; Yu, L. Solubilities of crystalline drugs in polymers: 
an improved analytical method and comparison of solubilities of indomethacin and 
nifedipine in PVP, PVP/VA, and PVAc. J. Pharm. Sci. 2010, 99 (9), 4023−4031. 
	 22	
8. Hancock, B. C.; Shamblin, S. L.; Zografi, G. Molecular mobility of amorphous 
pharmaceutical solids below their glass transition temperatures. Pharm. Res. 1995, 
12 (6), 799−806. 
9. Yoshioka, M.; Hancock, B. C.; Zografi, G. Crystallization of indomethacin from the 
amorphous state below and above its glass transition temperature. J. Pharm. Sci. 
1994, 83 (12), 1700−1705. 
10. Tian, Y.; Booth, J.; Meehan, E.; Jones, D. S.; Li, S.; Andrews, G. P. Construction 
of drug−polymer thermodynamic phase diagrams using Flory−Huggins interaction 
theory: identifying the relevance of temperature and drug weight fraction to phase 
separation within solid dispersions. Mol. Pharmaceutics 2013, 10 (1), 236−248. 
11. Tao, J.; Sun, Y.; Zhang, G. G.; Yu, L. Solubility of smallmolecule crystals in 
polymers: D-mannitol in PVP, indomethacin in PVP/VA, and nifedipine in PVP/VA. 
Pharm. Res. 2009, 26 (4), 855−864 
12. Marsac, P. J.; Shamblin, S. L.; Taylor, L. S. Theoretical and practical approaches 
for prediction of drug-polymer miscibility and solubility. Pharm. Res. 2006, 23 (10), 
2417−2426. 
13. Marsac, P. J.; Li, T.; Taylor, L. S. Estimation of drug-polymer miscibility and 
solubility in amorphous solid dispersions using experimentally determined interaction 
parameters. Pharm. Res. 2009, 26 (1), 139−151. 
14. Mahieu, A.; Willart, J. F.; Dudognon, E.; Danede, F.; Descamps, M. A new protocol 
to determine the solubility of drugs into polymer matrixes. Mol. Pharmaceutics 2013, 
10 (2), 560−566.  
15. Amharar, Y.; Curtin, V.; Gallagher, K. H.; Healy, A. M. Solubility of crystalline 
organic compounds in high and low molecular weight amorphous matrices above and 
below the glass transition by zero enthalpy extrapolation. Int. J. Pharm. 2014, 472 
(1−2), 241−247. 
16. Mohan, R.; Lorenz, H.; Myerson, A. S. Solubility measurement using differential 
scanning calorimetry. Ind. Eng. Chem. Res. 2002, 41 (19), 4854−4862. 
17. Xie, X. L.; Li, R. K. Y.; Tjong, S. C.; Tang, C. Y. Flory-huggins interaction 
parameters of LCP/thermoplastic blends measured by DSC analysis. J. Therm. Anal. 
Calorim. 2002, 70 (2), 541−548. 
18. Flory, P. J. Principles of polymer chemistry; Cornell University Press: Ithica, NY, 
1953. 
	 23	
19. Hoei, Y.; Yamaura, K.; Matsuzawa, S. A lattice treatment of crystalline solvent-
amorphous polymer mixtures on melting point depression. J. Phys. Chem. 1992, 96 
(26), 10584−10586. 
20. Koningsveld, R.; Stockmayer, W. H.; Nies, E. Polymer phase diagrams: a textbook; 
Oxford University Press: 2001. 
21. Zhao, Y.; Inbar, P.; Chokshi, H. P.; Malick, A. W.; Choi, D. S. Prediction of the 
thermal phase diagram of amorphous solid dispersions by Flory-Huggins theory. J. 
Pharm. Sci. 2011, 100 (8), 3196−3207. 
22. Lu, J.; Shah, S.; Jo, S.; Majumdar, S.; Gryczke, A.; Kolter, K.; Langley, N.; Repka, 
M. A. Investigation of phase diagrams and physical stability of drug-polymer solid 
dispersions. Pharm. Dev. Technol. 2015, 20 (1), 105−117. 
23. Nishi, T.; Wang, T. T. Melting point depression and kinetic effects of cooling on 
crystallization in poly (vinylidene fluoride)-poly (methyl methacrylate) mixtures. 
Macromolecules 1975, 8 (6), 909− 915. 
24. Lin, D.; Huang, Y. A thermal analysis method to predict the complete phase 
diagram of drug-polymer solid dispersions. Int. J. Pharm. 2010, 399 (1), 109−115. 
25. Paudel, A.; Van Humbeeck, J.; Van den Mooter, G. Theoretical and experimental 
investigation on the solid solubility and miscibility of naproxen in poly(vinylpyrrolidone). 
Mol. Pharmaceutics 2010, 7 (4), 1133−1148. 
26. Caron, V.; Tajber, L.; Corrigan, O. I.; Healy, A. M. A comparison of spray drying 
and milling in the production of amorphous dispersions of 
sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone. Mol. 
Pharmaceutics 2011, 8 (2), 532−542. 
27. Donnelly, C.; Tian, Y.; Potter, C.; Jones, D. S.; Andrews, G. P. Probing the Effects 
of Experimental Conditions on the Character of Drug-Polymer Phase Diagrams 
Constructed Using Flory-Huggins Theory. Pharm. Res. 2015, 32 (1), 167−179. 
28. Knopp, M. M.; Olesen, N. E.; Holm, P.; Löbmann, K.; Holm, R.; Langguth, P.; 
Rades, T. Evaluation of drug-polymer solubility curves through formal statistical 
analysis: comparison of preparation techniques. J. Pharm. Sci. 2015, 104 (1), 44−51. 
29. Knopp, M. M.; Olesen, N. E.; Holm, P.; Langguth, P.; Holm, R.; Rades, T. Influence 
of Polymer Molecular Weight on Drug-Polymer Solubility: A Comparison between 
Experimentally Determined Solubility in PVP and Prediction Derived from Solubility in 
Monomer. J. Pharm. Sci. 2015, DOI: 10.1002/jps.24410. 
	 24	
30. Gordon, M.; Taylor, J. S. Ideal copolymers and the second-order transitions of 
synthetic rubbers. i. non-crystalline copolymers. J. Appl. Chem. 1952, 2 (9), 493−500. 
31. Cook, R. D. Detection of influential observation in linear regression. Technometrics 
1977, 19, 15−18. 
32. Crowley, K. J.; Zografi, G. The effect of low concentrations of molecularly 
dispersed poly(vinylpyrrolidone) on indomethacin crystallization from the amorphous 
state. Pharm. Res. 2003, 20 (9), 1417− 1422. 
33. Pinal, R. Entropy of mixing and the glass transition of amorphous mixtures. Entropy 
2008, 10 (3), 207−223. 
34. Huang, Y.; Dai, W.-G. Fundamental aspects of solid dispersion technology for 
poorly soluble drugs. Acta Pharm. Sin. B 2014, 4 (1), 18−25. 
35. Greenhalgh, D. J.; Williams, A. C.; Timmins, P.; York, P. Solubility parameters as 
predictors of miscibility in solid dispersions. J. Pharm. Sci. 1999, 88 (11), 1182−1190. 
36. Alzghoul, A.; Alhalaweh, A.; Mahlin, D.; Bergstrom, C. A. Experimental and 
computational prediction of glass transition temperature of drugs. J. Chem. Inf. Model. 
2014, 54 (12), 3396−3403. 
 
 
 
 
 
 
 
  
	 25	
Figures 
 
Figure 1. Graphical illustration of the drug−polymer solubilities of the five systems 
predicted from the four different methods presented in Table 4. The white bars 
represent the liquid analogue solubility approach, the green bars represent the 
recrystallization method, the red bars represent the dissolution end point method, and 
the blue bars represent the melting point depression method. 
 
Figure 2. Representative equilibrium solubility curves of IMC (Xdrug) in PVP/VA 735 
as a function of temperature (T) from the three different thermal analysis methods. 
Green diamonds (⧫) represent the data from the recrystallization method, red circles 
(●) represent the data from the dissolution end point method, and blue squares (■) 
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represent the data from the melting point depression method. All data points are 
illustrated as averages (n = 3). The evolution of solubility of the three data sets has 
been fitted with the Flory−Huggins model (black curves) including the 95% prediction 
interval (dotted curves). The gray circles (●) represent the experimental relationship 
between Tg and Xdrug, and the gray curve is the theoretical Gordon−Taylor 
relationship. 
 
 
Figure 3. Decision tree for the screening of polymers suitable for glass solutions 
including the selection of the most optimal methods to predict drug−polymer solubility. 
Please note that this does not regard considerations of kinetic stability. 
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Tables 
Table 1. Experimental Physical and Thermodynamic Values of the Materials 
Measured by DSCa  and Density Measured by Helium Pycnometry 
a- Values are mean ± SD, n = 3. b- Average Mw according to the supplier. c- 
Amorphous density measured by helium pycnometry. 
 
  
Material Mw (g·mol-1)a 
Density (g·cm-
3)b 
Tg (°C) 
ΔCp (J·g-1·K-
1) 
ΔHm (J·g-
1) 
PCM 151.17 1.22 ± 0.01 23.3 ± 0.2 0.64 ± 0.04 
193.5  ± 
1.7 
CAP 323.13 1.47 ± 0.00 29.5 ± 0.3 0.54 ± 0.02 
115.1  ± 
0.3 
CCX 381.37 1.35 ± 0.01 56.8 ± 0.0 0.38 ± 0.02 99.4  ± 0.8 
IMC 357.79 1.31 ± 0.01 45.4 ± 0.1 0.39 ± 0.01 
116.7  ± 
0.4 
FDP 384.26 1.29 ± 0.00 45.2 ± 0.1 0.36 ± 0.01 82.6  ± 0.4 
Vinylacetate 86.09 0.93 ± 0.00 - - - 
N-vinylpyrrolidone 111.14 1.04 ± 0.00 - - - 
PVP/VA 335 28,000 1.18 ± 0.00 68.5 ± 0.3 0.34 ± 0.01 - 
PVP/VA 535 36,700 1.19 ± 0.01 91.3 ± 0.1 0.34 ± 0.02 - 
PVP/VA 635 38,200 1.18 ± 0.01 
105.3 ± 
0.2 
0.33 ± 0.02 - 
PVP/VA 735 56,700 1.18 ± 0.01 
117.2 ± 
0.1 
0.33 ± 0.02 - 
PVP K17 10,000 1.20 ± 0.00 
125.2 ± 
0.4 
0.31 ± 0.01 - 
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Table 2. Solubility of the Drugs in NVP and VA and Predicted Solubilities in the Pure 
Polymers and the Five Drug− Copolymer Systems 
 
PCM:PVP/VA 
335 
CAP:PVP/VA 
535 
CCX:PVP/VA 
635 
IMC:PVP/VA 
735 
FDP:PVP 
K17 
Values 
predicted from 
the liquid 
analogue 
solubility 
approach 
     
Solubility in NVP 
at 25°C (g/g) 
0.34 0.71 0.61 0.52 0.12 
Predicted 
solubility in PVP 
at 25°C (g/g) 
0.18 0.52 0.41 0.31 0.05 
Solubility in VA at 
25°C (g/g) 
0.00 0.01 0.09 0.01 0.09 
Predicted 
solubility in PVAc 
at 25°C (g/g) 
0.00 0.00 0.03 0.01 0.04 
PVP/PVAc ratio 
(w/w)a 
30/70 50/50 60/40 70/30 100/0 
Predicted 
solubility in 
PVP/VA 
copolymer  at 
25°C (g/g) 
0.05 0.26 0.26 0.22 0.05 
a- Weight ratios according to supplier information. 
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Table 3. Summary of Raw Dataa. 
 Recrystallization method 
 PCM:PVP/VA 335 CAP:PVP/VA 535 CCX:PVP/VA 635 IMC:PVP/VA 735 FDP:PVP K17 
Ta (°C) Tg (°C) 
Xdrug 
(w/w) 
Tg (°C) 
Xdrug 
(w/w) 
Tg (°C) 
Xdrug 
(w/w) 
Tg (°C) 
Xdrug 
(w/w) 
Tg (°C) 
Xdrug 
(w/w) 
150 - - - - 
72.0 ± 
0.2 
0.779 
56.2 ± 
0.1 
0.834 - - 
145 - - - - 
74.3 ± 
0.1 
0.744 
60.2 ± 
0.4  
0.765  - - 
140 - - - - 
76.5 ± 
0.2 
0.710 
62.3 ± 
0.7 
0.726 - - 
135 
45.6 ± 
0.3 
0.414 
40.2 ± 
0.3 
0.772 
78.0 ± 
0.3 
0.688 
64.1 ± 
0.7 
0.693 
55.5 ± 
0.4 
0.743 
130 
47.2 ± 
0.1 
0.385 
44.8 ± 
0.2 
0.709 
79.4 ± 
0.1 
0.666 
65.5 ± 
0.5 
0.667 
63.6 ± 
0.2 
0.644 
125 
48.0 ± 
0.1 
0.370 
48.4 ± 
0.5 
0.660 - - 
67.2 ± 
0.9 
0.634 
67.1 ± 
0.1 
0.601 
120 
49.4 ± 
0.5 
0.343 
51.4 ± 
0.5 
0.619 - - - - 
70.2 ± 
0.3 
0.563 
115 - - 
53.1 ± 
0.1 
0.595 - - - - - - 
 Dissolution endpoint method 
 PCM:PVP/VA 335 CAP:PVP/VA 535 CCX:PVP/VA 635 IMC:PVP/VA 735 FDP:PVP K17 
Xdrug 
(w/w) 
Tend (°C) Tend (°C) Tend (°C) Tend (°C) Tend (°C) 
0.95 172.00 ± 0.04 151.24 ± 0.03a 163.77 ± 0.31a 161.81 ± 0.02a 141.47 ± 0.16a 
0.90 171.54 ± 0.26 150.49 ± 0.13 162.78 ± 0.80 160.80 ± 0.02 140.51 ± 0.26 
0.85 169.66 ± 0.03 149.10 ± 0.05 161.05 ± 0.83 159.38 ± 0.13 139.22 ± 0.13 
0.8 168.81 ± 0.06 146.65 ± 0.12 158.25 ± 0.61 156.87 ± 0.08 137.29 ± 0.15 
0.75 168.55 ± 0.44 143.86 ± 0.04 154.51 ± 0.62 152.34 ± 0.15 134.93 ± 0.22 
0.70 167.37 ± 0.31 140.21 ± 0.52 150.09 ± 0.26 147.25 ± 0.30 132.04 ± 0.09 
0.65 165.09 ± 0.62  - 148.32 ± 0.19a 140.50 ± 1.23  - 
0.60 163.46 ± 0.55 - - 132.42 ± 1.02 - 
 Melting point depression method 
 PCM:PVP/VA 335 CAP:PVP/VA 535 CCX:PVP/VA 635 IMC:PVP/VA 735 FDP:PVP K17 
Xdrug 
(w/w) 
Tm (°C) Tm (°C) Tm (°C) Tm (°C) Tm (°C) 
0.95 168.50 ± 0.01 148.38 ± 0.10 160.13 ± 0.04 158.26 ± 0.11 140.75 ± 0.11a 
0.90 167.51 ± 0.17 145.88 ± 0.08 157.58 ± 0.03 154.76 ± 0.06 139.85 ± 0.02 
0.85 166.38 ± 0.33 141.90 ± 0.40 152.15 ± 0.40 149.99 ± 0.34 138.55 ± 0.01 
0.8 164.76 ± 0.28 139.24 ± 0.27 145.49 ± 0.21 144.62 ± 0.09 138.09 ± 0.01 
0.75 159.82 ± 0.50 - - - - 
0.70 156.09 ± 0.33 - - - 137.29 ± 0.25 
0.65 151.12 ± 0.14 - - - - 
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a- For the recrystallization method, the glass transition temperatures of the annealed 
material (Tg) and the corresponding drug fraction (Xdrug) were measured at different 
annealing temperatures (Ta). For the dissolution end point and melting point 
depression methods, the dissolution end point (Tend) and melting point (Tm) were 
measured at different drug fractions (Xdrug) (values are mean ± SD, n = 3). bData 
detected as outlier by calculation of Cook’s distance and excluded.31 
 
  
0.60 142.54 ± 0.11 - - - 136.90 ± 0.01 
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Table 4. Drug− Polymer Solubilities of the Five Systems Predicted from the Four 
Different Methods along with the Flory− Huggins Interaction Parameter χ  and the 
95% Prediction Interval. 
  
PCM:PVP/VA 
335 
CAP:PVP/VA 
535 
CCX:PVP/VA 
635  
IMC:PVP/VA 
735 
FDP:PVP 
K17 
Values 
predicted from 
the liquid 
analogue 
solubility 
approach 
     
Predicted 
solubility in 
PVP/VA 
copolymer  at 
25°C (g/g) 
0.05 0.26 0.26 0.22 0.05 
Values 
predicted from 
the 
recrystallization 
method 
     
Interaction 
parameter χ 
-1.2 ± 0.3 -4.1 ± 1.0 -5.2 ± 0.9 -6.3 ± 1.6 -2.2 ± 0.6 
Solubility at 
25°C (g/g) 
0.03 0.14 0.17 0.19 0.07 
95% prediction 
interval at 25°C 
0.02-0.04 0.08-0.20 0.12-0.21 0.11-0.25 0.04-0.10 
Values 
predicted from 
the melting 
point 
depression 
method 
     
Interaction 
parameter χ 
-1.3 ± 0.8 -3.9 ± 1.8 -5.7 ± 1.1 -8.8 ± 3.7 -1.5 ± 3.0 
Solubility at 
25°C (g/g) 
0.05 0.15 0.25 0.35 0.06 
95% prediction 
interval at 25°C 
0.02-0.09 0.05-0.26 0.19-0.31 0.18-0.45 0.00-0.25 
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Values 
predicted from 
the dissolution 
endpoint 
method 
     
Interaction 
parameter χ 
-0.6 ± 0.9 -1.9 ± 0.8 -2.9 ± 1.6 -2.9 ± 0.9 -1.4 ± 0.6 
Solubility at 
25°C (g/g) 
0.02 0.05 0.06 0.06 0.08 
95% prediction 
interval at 25°C 
0.01-0.04 0.03-0.09 0.01-0.14 0.03-0.10 0.05-0.12 
 
Table 5. Advantages and Disadvantages of the Four Different Methods 
advantages disadvantages 
Liquid Analogue Solubility Approach 
simple shake-flask method 
 
requires liquid analogue 
 
measures at room temperature 
 
predicts the solubility in a liquid rather 
than a solid 
 
enables multiple screening 
 
 
Recrystallization Method 
 
heating rate independent 
 
time-consuming 
 
applicable for most polymers with 
Tg > 90 °Ca 
may overestimate solubility 
 
Dissolution End Point Method 
 
applicable for most polymers with 
Tg < 120 °Ca 
heating rate and milling condition 
dependent 
 
relatively fast may underestimate solubility 
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 not applicable if drug is thermally 
decomposed at Tm 
 
Melting Point Depression Method 
 
applicable for most polymers with 
Tg < 120 °Ca 
 
heating rate dependent 
 
relatively fast 
 
may overestimate solubility 
 
 requires 100% crystallinity 
 
 not applicable if drug is thermally 
decomposed at Tm 
 
a- Estimation based on a general assumption of the Tm (>140 °C) and Tg (<70 °C) 
of low molecular weight drugs.36 
 
